Open in interactive viewer → charts, metric popovers & call review

Immunovant: The Data Arrived Early; the FDA Didn't

A surprise p-value in refractory RA hands Roivant a third pillar — and no regulatory path — while LISRAYA's first five weeks book $31 million and management quietly shelves Sjögren's.
IMVT · Earnings Call · 2026-11-09

A p-value nobody planned for

Immunovant's quarter arrived through its parent's microphone — this is Roivant's fiscal Q2 call — and Matthew Gline opened by conceding the biggest item on the tape was not on his script: “I want to jump now to another update that I wasn't totally expecting to provide today, but it's a great update” — Matthew Gline, CEO · 2026-11-09. That update was Period 2 of the IMVT-1402 difficult-to-treat RA study. The design is a randomized withdrawal trial: 118 responders from the open-label period re-randomized to 600 mg, 300 mg, or placebo, with 117 analyzed. Roughly 92.5% of patients on the high dose held an ACR20 response at week 28 versus about 75% on placebo, and the 600 mg arm cleared a p-value. ACR50 separated too, at 80% versus 56%. The genuinely surprising part is the middle arm: 300 mg behaved like placebo. As Gline put it on the call, “the fact that we were able to preserve north of 90% of those responders on drug is pretty exciting” — Matthew Gline, CEO · 2026-11-09 — particularly in patients who had already failed TNFs, JAKs and, in some cases, IL-6s. That dose dissection is the whole commercial thesis in miniature. Management has spent several quarters arguing that deeper IgG suppression is what separates the winners in FcRn biology, and Period 2 is the cleanest clinical proof yet that a shallower dose will not do: “it's clear to us that we have a competitive advantage by being able to more deeply suppress IgG and autoantibody levels, and we're trying to preserve that advantage” — Matthew Gline, CEO · 2026-11-09. It is also why they refused to show IgG or autoantibody data — a refusal that reads as strategic rather than evasive. The hole in the story is regulatory. Management had previously promised to deliver the data and the FDA conversation as one package:

My dream, our dream for the second half of this year is that we can come back with everything tied as nicely into a bow as possible, which is to say the period 2 data, the FDA conversation, maybe some further analysis of patient experience... all shared at the same time.

Matthew Gline, CEO · 2026-08-06
They hit a p-value unexpectedly, disclosed it alone, and left the design questions — one Phase III or two, what primary endpoint, parallel versus withdrawal — wide open: “we don't know on either of those questions for sure” — Matthew Gline, CEO · 2026-11-09. The company says the discussions will resolve "later this year or early next year." There is a real asset here and no filing calendar attached to it, which is a strange combination to hand a market that just took the stock down 21.8% from its August peak.

Five weeks of LISRAYA, and the inventory question

LISRAYA (brepocitinib in dermatomyositis) was approved in late August and produced $31 million of net revenue across roughly five weeks. "Hundreds" of patients were on paid drug at September 30 and "many hundreds" now, with many hundreds of prescribers writing. But the revenue is booked when specialty pharmacies buy, not when patients fill, and Gline conceded the gap: “there was a meaningful amount of drug held by the pharmacies at the end of the quarter, and it has all been dispensed now” — Matthew Gline, CEO · 2026-11-09. That implies a tailwind to the September quarter and a modest December headwind — the classic first-launch optics problem, amplified by a five-week window in which a few days of timing swings the arithmetic. Analysts pushed twice on whether the $31 million squares with "hundreds" of patients; they got a fair explanation and no bridge. Access is the variable worth watching. Early payer dynamics have been benign, ranging from national plans requiring only a prior systemic immunosuppressant to others attempting tighter controls. That will not last, and it — not demand — is the swing factor for 2027.

What management stopped saying

Two themes went quiet, and the silence is louder than the headlines. First, Sjögren's. A year ago the pitch was confident: “we think we have a real shot at best-in-class” — Matthew Gline, CEO · 2025-11-10. On this call, Sjögren's was effectively written down: “argenx's futility analysis had a really low bar, and they failed in 500 patients... we're just thinking it's relatively unlikely at this point” — Matthew Gline, CEO · 2026-11-09. Add the earlier CLE miss and 1402's story has narrowed sharply this year — NIU is a win, RA is a surprise win, and two immunology expansions have closed. Second, Graves' disease. It was a marquee keyword in prior quarters and is essentially absent from this one. Asked directly about the 2027 Graves' and MG readouts, Gline offered only that enrollment is strong and “I do not have an update to share today” — Matthew Gline, CEO · 2026-11-09. With the RA program waiting on the agency, the near-term value driver now depends entirely on a study set the company has stopped dating. The financials are consistent with a company funding a widening Phase III footprint. R&D reached $143 million in the latest quarter, up 41% year over year, driving an operating loss of $153 million. The cushion is real — $4.2 billion in cash after the Moderna litigation receipts, plus $280 million of buybacks (9.4 million shares) in the first half — though the reported cash runway of 6.4 quarters understates the balance sheet and overstates the urgency; this is a company with years, not quarters, of funding.

The tape and the setup

The stock is down 8.9% over 90 days and 21.8% from its August 19 high of $44.96, against a lifetime return still north of 250%. So the market has been de-rating the name into a report that contained, by any clinical standard, two good datasets. That divergence is the story: investors are not arguing about the biology, they are arguing about sequencing — inventory-flattered launch revenue, an FDA conversation without a date, a shelved Sjögren's program, and Graves' gone quiet until 2027. The December 9 Investor Day now has to carry the commercial case that the call deferred. What changed at Immunovant this quarter is not the science. It is that the company now has three pillars and no timetable — and the market has started pricing the timetable instead of the pillars.